Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 113,400 shares, a decrease of 30.0% from the November 30th total of 162,100 shares. Based on an average daily volume of 500 shares, the days-to-cover ratio is presently 226.8 days.

Molecular Partners Stock Up 5.8 %

OTCMKTS MLLCF opened at $6.17 on Monday. Molecular Partners has a 52 week low of $5.16 and a 52 week high of $32.00. The firm's 50-day simple moving average is $6.39 and its two-hundred day simple moving average is $6.19.

Get Molecular Partners alerts:

Molecular Partners Company Profile

(Get Rating)

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.

See Also

• Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
• MarketBeat: Week in Review 12/26 – 12/30
• The Dogs Of Tech: It's Time For A Bite Of These Stocks
• Does This Acquisition Make Microsoft a Bear Market Buy?
• Should You Warm up to Generac Stock for the Winter?
• Is Kintara Therapeutics A Hidden Gem?

Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.